Antibody response after vaccination with tetanus and diphtheria toxoids in human T-cell lymphotropic virus type 1 asymptomatic carriers

Biasutti, Cláudia; Moraes-Pinto, Maria Isabel de; Segurado, Aluísio Cotrim

doi:10.1016/j.vaccine.2008.03.068

Cited by 2 publications

(3 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this study, we showed that the level of antibody production (total anti-TT IgG) in HTLV-1 carriers was lower than that observed in UC after immunization with TT. In this study, the TT immunization schedule, the evaluation time of the immune response after immunization and the determination of IgG production were different from those presented by Biasutti et al [34]. However, although contradictory, we are comfortable with our results because the evaluation of IgG1 production revealed a similar pattern as that found for the total anti-TT IgG production.…”

Section: Discussioncontrasting

confidence: 61%

See 1 more Smart Citation

Impairment of the humoral and CD4 + T cell responses in HTLV-1-infected individuals immunized with tetanus toxoid

et al. 2016

View full text Add to dashboard Cite

T cells from HTLV-1-infected individuals have a decreased ability to proliferate after stimulation with recall antigens. This abnormality may be due to the production of regulatory cytokine or a dysfunctional antigen presentation. The aims of this study were to evaluate the antibody production and cytokine expression by lymphocytes before and after immunization with tetanus toxoid (TT) and to evaluate the immune response of monocytes after stimulation with TT and frequency of dendritic cells (DC) subsets. HTLV-1 carriers (HC) and uninfected controls with negative serology for TT were immunized with TT, and the antibody titers were determined by ELISA as well as the cell activation markers expression by monocytes. The frequencies of DC subsets were determined by flow cytometry. Following immunization, the IgG anti-TT titers and the frequency of CD4+ T cells expressing IFN-γ, TNF and IL-10 in response to TT were lower in the (HC) than in the controls. Additionally, monocytes from HC did not exhibit increased HLA-DR expression after stimulation with TT, and presented low numbers of DC subsets, therefore, it’s necessary to perform functional studies with antigen-presenting cells. Collectively, our finding suggests that HC present an impairment of the humoral and CD4+ T cell immune responses after vaccination.

show abstract

Section: Discussioncontrasting

confidence: 61%

“…In a previous study evaluating the anti-TT antibody production in HTLV-1-infected subjects, it was found that the HC produced a high amount of neutralizing anti-TT antibody [34]. In this study, we showed that the level of antibody production (total anti-TT IgG) in HTLV-1 carriers was lower than that observed in UC after immunization with TT.…”

Section: Discussionmentioning

confidence: 48%

Impairment of the humoral and CD4 + T cell responses in HTLV-1-infected individuals immunized with tetanus toxoid

et al. 2016

View full text Add to dashboard Cite

show abstract

“…The measurement of anti-tetanus toxoid immunoglobulin G (IgG) levels is of value in (i) determining the rates of immunity within broad populations or the immune status of individuals who may be at risk of infection (15), (ii) assessing responses to vaccination and immunization schedule efficacy (2,5,15), and (iii) evaluating individuals for potential immunodeficiency disorders (1,3).…”

mentioning

confidence: 99%

Comparison of Five Commercial Anti-Tetanus Toxoid Immunoglobulin G Enzyme-Linked Immunosorbent Assays

Perry¹,

Hayes²,

Cox³

et al. 2009

Clin Vaccine Immunol

View full text Add to dashboard Cite

Five commercially available enzyme-linked immunosorbent assays for the measurement of anti-tetanus toxoid immunoglobulin G (IgG) antibodies were evaluated for performance. The data suggest that there are manufacturer-dependent differences in sensitivity and accuracy for the determination of tetanus toxoid IgG antibodies that could result in different diagnostic interpretations.The measurement of anti-tetanus toxoid immunoglobulin G (IgG) levels is of value in (i) determining the rates of immunity within broad populations or the immune status of individuals who may be at risk of infection (15), (ii) assessing responses to vaccination and immunization schedule efficacy (2,5,15), and (iii) evaluating individuals for potential immunodeficiency disorders (1, 3).The World Health Organization guidelines suggest that IgG antibody titers above 0.01 IU/ml afford minimal protection against infection and titers above 0.1 IU/ml provide substantial protection (2).Significant differences in performance against international reference preparations and clinical interpretation of a number of patient samples have been found previously in commercial anti-tetanus toxoid enzyme-linked immunosorbent assays (ELISAs) (14). The present study confirms these findings, increases the number of commercial assays evaluated, and extends the comparison of their performance in terms of diagnostic interpretations.Normal human serum samples were obtained from Research Sample Bank, Inc., Pompano Beach, FL, and Golden West Biologicals Inc., Temecula, CA, and stored at Ϫ20°C prior to testing. The reference sample NIBSC 76/589 (NIBSC, Hertfordshire, United Kingdom) was used to evaluate the calibration of the ELISA kits. It was chosen because it is correlated against the mouse in vivo neutralization test, the concentration was more appropriate for the measuring ranges of clinically relevant ELISA kits, and it has been used previously (14). For use, NIBSC 76/589 was reconstituted according to the manufacturer's instructions (working concentration of 1 IU/ ml), serially diluted with distilled water to a final concentration of 0.03 IU/ml, and further diluted immediately into the appropriate sample diluents.Anti-tetanus toxoid IgG antibodies were measured according to the manufacturers' instructions by using the following ELISA kits, with the measuring ranges in parentheses: Euroimmun, Lübeck, Germany (0.01 to 10 IU/ml); Scimedx Corp., Denville, NJ (0.1 to 5 IU/ml); Serion-Verion, Würzburg, Germany (0.1 to 5 IU/ml); The Binding Site, Birmingham, United Kingdom (the TBS assay; 0.01 to 7 IU/ml); and Genzyme Virotech, Rüsselsheim, Germany (0.1 to 5 IU/ml). Results were generated in accordance with the manufacturer's instructions. Assays were considered valid when quality control parameters were in the range specified in the manufacturer's product insert. Intraassay precision was measured by using three serum samples (low, medium, and high levels) and assayed in seven-well repeats at the same time. For interassay precision, the same measurements were performed ...

show abstract

Antibody response after vaccination with tetanus and diphtheria toxoids in human T-cell lymphotropic virus type 1 asymptomatic carriers

Cited by 2 publications

References 16 publications

Impairment of the humoral and CD4 + T cell responses in HTLV-1-infected individuals immunized with tetanus toxoid

Impairment of the humoral and CD4 + T cell responses in HTLV-1-infected individuals immunized with tetanus toxoid

Comparison of Five Commercial Anti-Tetanus Toxoid Immunoglobulin G Enzyme-Linked Immunosorbent Assays

Contact Info

Product

Resources

About